



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 18 Dec 2018 (#38)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)

## 1. HEAL Initiative: Back Pain Consortium (BACPAC) Research Program: Mechanistic Research Centers (U19 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AR-19-026\)](#)

**Type:** U19

**Application Due Date:** March 20, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites research applications to plan and implement Interdisciplinary Mechanistic Research Centers (MRC) in Low Back Pain (LBP) with the NIH Back Pain Consortium (BACPAC) Research Program. BACPAC is a patient-centric research program focused on translational and clinical research for discovery of chronic low back pain (cLBP) mechanisms, and on identification and testing of new interventions targeted to individual patients. BACPAC will utilize novel analytics and technologies to extensively phenotype patients with low back pain (LBP), develop an integrated model of cLBP, produce new and improved diagnostic and treatment algorithms, and test new therapies in Phase 2 clinical trials. The MRCs will conduct translational and clinical research projects addressing critical gaps and opportunities in LBP with advanced analytics and approaches to improve understanding of disease and identify new targets for intervention. The MRCs will generate data for deep patient phenotyping and for the development of patient-based algorithms. The MRCs will conduct collaborative, adaptive design, multimodal therapy studies in cLBP with the aim of improving the use of therapies targeted to individual patients. The MRCs will run in parallel and synergize with projects supported in the BACPAC Data Integration, Algorithm Development and Operations Management Center, Technology Research Sites and Phase 2 Clinical Trials. BACPAC is part of the multi-pronged HEAL (Helping to End Addiction Long-term) Initiative, an aggressive effort to speed scientific solutions to stem the national opioid public health crisis. (<https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative>). HEAL will build on extensive, well-established NIH research to address the opioid crisis and provide safer therapies for people with pain.

**Budget:** The NIAMS intends to commit up to \$15.1M in FY 2019 to fund 3-5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

## 2. HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AR-19-028\)](#)

**Type:** UH2/3

**Application Due Date:** March 20, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) invites applications for the Technology Research Site component of the NIH Back Pain Consortium (BACPAC) Research Program. BACPAC is a patient-centric-research program that will focus on translational and clinical research for discovery of chronic low back pain (cLBP) mechanisms, and on identification and testing of new interventions targeted to the individual patient. The Research Program will utilize novel analytics and technologies to extensively phenotype patients with low back pain, develop an integrated model of cLBP, produce new and improved diagnostic and treatment algorithms, and will conduct traditional Phase 2 Clinical Trials as well as sequential, adaptive, phase 2/proof of concept clinical studies in stratified patient populations. The Technology Research Sites will develop, test and deploy novel analytic tools, technologies and/or methods (TTM) that will improve our understanding of mechanisms of cLBP. Collectively, they will contribute to the development of an integrated model of cLBP. The technology research and development will run in parallel and will synergize with projects supported in the BACPAC Mechanistic Research Centers, the Data Integration, Algorithm Development and Operations Management Center and the Phase 2 Clinical trials. Successful analytic TTM will be utilized clinically in BACPAC Phase 2 Clinical Trials and in multimodal, sequential, adaptive clinical studies in stratified patient populations. Where applicable, TTM developed by the Tech Sites will improve the diagnosis, treatment and prevention of recurrences of cLBP and/or be useful for defining different mechanisms in different patients and contribute to the development of algorithms for individualized treatment plans.

**Budget:** The NIAMS intends to commit an estimated total of \$2.6M to fund 4-6 awards. The application budgets for UH2 phase are limited to \$400,000 Direct Costs per year. The application budgets for UH3 phase are not limited but need to reflect the actual needs of the proposed project. The maximum project period for the UH2 phase is two years, and the maximum project period for the UH3 phase is four years. The duration of the combined UH2/UH3 award cannot exceed five years.

### 3. HEAL Initiative: Back Pain Consortium (BACPAC) Research Program: Phase 2 Clinical Trials (UG3/UH3 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-AR-19-029\)](#)

**Type:** UGH3

**Application Due Date:** February 26, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites research applications to plan and implement Phase 2 clinical trials (Phase 2CT) in chronic Low Back Pain (cLBP) with the NIH Back Pain Consortium (BACPAC) Research Program. BACPAC will carry out a patient centric-research program focused on translational and clinical research for discovery of chronic low back pain mechanisms, and on identification and testing of new interventions targeted to individual patients. BACPAC will utilize novel analytics and technologies to extensively phenotype patients with low back pain, develop an integrated model of cLBP and produce new and improved diagnostic and treatment algorithms. BACPAC Phase 2 clinical trials (Phase 2CT) will evaluate interventions including medications, biologics, procedures, medical and assistive devices and technologies, diagnostic testing, behavioral change, rehabilitation strategies, complementary therapies for cLBP. The studies will use randomized trial design as well as adaptive, phase 2/proof of concept design studies in stratified patient populations. Clinical trials may be conducted within the infrastructure of the Early Phase Pain Investigation Clinical Network (EPPIC-Net) (formerly known as the Clinical Trial Network for Pain Research CTNPR). The Phase 2CTs will run in parallel and will synergize with projects supported in the BACPAC Mechanistic Research Centers, the Data Integration, Algorithm Development and Operations Management Center and the Technology Research Sites.

**Budget:** NIAMS intends to commit \$1.3M to fund up to 8 awards in Phase I in FY2019. NIAMS expects to support up to five UH3 awards. Application budgets are limited to \$200,000 Direct Costs for the entire UG3 planning phase. Application budgets for the UH3 phase are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period for the UG3 phase is two years, and the maximum project period for the UH3 phase is four years. The duration of the combined UG3/UH3 award cannot exceed five years.

### 4. HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-EB-18-003\)](#)

**Type:** U18

**Application Due Date:** March 22, 2019, June 20, 2019, October 22, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to support preclinical development and demonstration of safe, effective, and non-addictive device-based technologies and approaches to treat pain. The goal of the program is to demonstrate treatment using credible neural targets for device-based interventions and/or diagnostics for pain, building upon the latest mechanistic knowledge about the anatomy and physiology of central, spinal, and peripheral pathways involved in pain. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. This is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in the development of the project plan and monitoring of research progress.

**Budget:** Issuing IC and partner components intend to commit an estimated total of \$3M to fund 5-10 awards in FY2019. Awards issued under this FOA are part of funds set aside to support the HEAL (Helping to End Addiction Long-term) initiative. Application budgets are not limited but need to reflect the actual needs of the proposed project. Budgets should rarely exceed \$500,000 direct cost per year. The total project period for an application submitted in response to this funding opportunity may not exceed 3 years.

### 5. Contraception Research Centers Program (U54 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-HD-19-023\)](#)

**Type:** U54

**Application Due Date:** February 13, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The primary purpose of this funding opportunity announcement (FOA) is to support and facilitate multidisciplinary approaches to the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Research Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success, and also behavioral and social science research projects to study contraceptive use and non-use of marketed products or products in clinical development. The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research.

**Budget:** The NICHD intends to commit \$2.0 million in FY 2019 to fund one award. A Center should propose a budget that reflects the actual needs of the proposed projects and costs; such a budget must not exceed \$1.3 million per year in direct costs, excluding third party F&A. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

### 6. Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-19-104\)](#)

**Type:** X01

**Application Due Date:** February 21, 2019 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing may be available for tumor or affected tissue when justified. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

**Budget:** Not applicable; there are no funds associated with a resource access award. The maximum project period is 1 year

## 7. Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-19-098\)](#)

**Type:** K43

**Application Due Date:** November 7, 2019 and November 4, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-19-051. The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>), including "low-income," "lower-middle-income," and "upper-middle-income" countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

**Budget:** NIH will contribute up to \$75,000 (for a minimum of 75% effort or 9 person months) per year toward the salary of the career award recipient. NIH will contribute up to \$30,000 per year toward the research development costs of the award recipient, which must be justified and consistent with the stage of development of the candidate and the proportion of time to be spent in research or career development activities. Salary for mentors, secretarial and administrative assistants, etc. is not allowed

## 8. Physical Sciences-Oncology Network (PS-ON): Physical Sciences-Oncology Projects (PS-OP) (U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-19-101\)](#)

**Type:** U01

**Application Due Date:** January 30, 2019; July 30, 2019; January 30, 2020; July 30, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the Physical Sciences-Oncology Network (PS-ON) is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.

**Budget:** Direct costs requested may not exceed \$499,999 per year. The budget must reflect the actual needs of the proposed project. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)